Myriad RBM, Sanofi Partner on Biomarkers for Diabetes | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Monday that its wholly owned subsidiary Myriad RBM has entered into a diabetes biomarker collaboration with Sanofi and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.